Treatment progress of chronic lymphocytic leukemia
10.3760/cma.j.issn.1009-9921.2019.01.002
- VernacularTitle:慢性淋巴细胞白血病治疗进展
- Author:
Zhijian CAO
1
;
Jun MA
Author Information
1. 哈尔滨血液病肿瘤研究所 150010
- Keywords:
Leukemia,lymphocytic,chronic;
Immunotherapy;
Bruton's tyrosine kinase inhibitor;
Chimeric antigen receptor T-cell
- From:
Journal of Leukemia & Lymphoma
2019;28(1):5-7
- CountryChina
- Language:Chinese
-
Abstract:
Chronic lymphocytic leukemia (CLL) is one of the common lymphoid malignancies. Single agent ibrutinib has 74％ progression-free survival (PFS) rate in RESONATE-2 trial, but ibrutinib-based therapy combined with obinutuzumab or rituximab in recent iLLUMINTE trial and ALLIANCE trail have 79％ and 88％ PFS rate respectively, which brings encouraging results. New inhibitors and chimeric antigen receptor T-cell (CAR-T) immunotherapy provide new treatment regimens for CLL patients who relapsed after receiving ibrutinib. The clinical trials have been done in phase Ⅰ/Ⅱ.
